NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Why is BioAge being Investigated? BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The company's lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss. During the relevant period, the company stated that azelaprag was well-tolerated in 265 individuals across eight Phase 1 clinical trials and that following the company's IPO ...Full story available on Benzinga.com

Bill Ackman once sought insights from Berkshire Hathaway's chairman Warren Buffett about the investment appeal of the Salomon Brothers. What Happened: At the 1994 Berkshire Hathaway annual meeting, Ackman, then a young hedge fund manager, raised a critical question about Salomon Brothers. He directed his question to Buffett, asking, "What is the appeal of the business to you, given its leverage of 30-to-1 and relatively modest returns on equity?" Buffett responded thoughtfully, acknowledging the high leverage involved but underscoring the importance of leadership in managing such risks. The Oracle of Omaha praised the efforts of Salomon’s leaders, including Deryck Maughan, Bob Denham, and John McFarlane, who navigated the company through challenging times without prior discussions on compensation or guarantees. See Also: Samsung Galaxy S25 Ultra And S25+ Leaks Feature Sleek Curved Design And Slimmer Bezels Than Apple’s iPhone 16 Pro Max “The test will ...Full story available on Benzinga.com

On Friday, the U.S. Food and Drug Administration approved Eli Lilly and Co.’s (NYSE:LLY) weight loss drug Zepbound for treating sleep apnea What Happened: The FDA’s decision makes Zepbound the first approved drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea, or OSA. “Too often, OSA is brushed off as ‘just snoring,'” said Julie Flygare, CEO of Project Sleep, in Eli Lilly’s press release. The condition affects an estimated 80 million Americans, with 20 million experiencing moderate-to-severe forms. See Also: Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo’s Dominance In a separate release, the FDA underscored that Zepbound should be used in conjunction with a reduced-calorie diet and ...Full story available on Benzinga.com